NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by American Century Companies Inc.

Key Points

• American Century Companies Inc. increased its holdings in NewAmsterdam Pharma by 52.6%, owning 528,830 shares worth approximately $10.83 million at the end of the first quarter.
• Wall Street analysts are optimistic about NewAmsterdam Pharma, with several firms, including Wells Fargo and Royal Bank of Canada, issuing "buy" ratings and setting prices targets around $39 to $45.
• The company's stock recently surged by 2.0%, trading at $25.19, after reporting better-than-expected earnings per share of ($0.15) compared to the consensus estimate of ($0.52).

American Century Companies Inc. boosted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 52.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 528,830 shares of the company's stock after buying an additional 182,258 shares during the quarter. American Century Companies Inc. owned 0.48% of NewAmsterdam Pharma worth $10,825,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after buying an additional 596 shares in the last quarter. Legal & General Group Plc boosted its stake in NewAmsterdam Pharma by 24.8% during the fourth quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock valued at $590,000 after buying an additional 4,556 shares in the last quarter. Northern Trust Corp bought a new position in NewAmsterdam Pharma during the fourth quarter valued at about $556,000. Barclays PLC boosted its stake in NewAmsterdam Pharma by 120.0% during the fourth quarter. Barclays PLC now owns 16,713 shares of the company's stock valued at $429,000 after buying an additional 9,117 shares in the last quarter. Finally, Arizona State Retirement System bought a new position in NewAmsterdam Pharma during the first quarter valued at about $215,000. Institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several research reports. Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a research note on Monday. They set an "overweight" rating and a $45.00 target price for the company. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target for the company. Citigroup started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target for the company. Finally, Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, NewAmsterdam Pharma has an average rating of "Moderate Buy" and an average target price of $41.55.

NewAmsterdam Pharma Trading Up 2.0%

Shares of NewAmsterdam Pharma stock opened at $25.19 on Wednesday. The stock has a 50-day moving average price of $21.93 and a 200 day moving average price of $20.27. The company has a market cap of $2.84 billion, a P/E ratio of -15.55 and a beta of -0.02. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.37. The firm had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, Director James N. Topper acquired 2,520 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average cost of $18.43 per share, with a total value of $46,443.60. Following the purchase, the director owned 3,024,873 shares in the company, valued at approximately $55,748,409.39. The trade was a 0.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Douglas F. Kling sold 51,043 shares of the stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total value of $1,077,007.30. Following the completion of the sale, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $928,400. This represents a 53.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 12,835 shares of company stock valued at $248,134 and sold 248,612 shares valued at $5,240,387. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.